Here are relevant reports on : diabetes-devices-market
-
Home Healthcare Market by Product (Therapeutic, Testing, Screening, Monitoring, Mobility Care), Service (Nursing, Infusion Therapy, Rehabilitation, Palliative Care), Indication (Cancer, Diabetes, CVD, Respiratory, Wound Care) - Global Forecast to 2030
The global home healthcare market, valued at US$285.3 billion in 2024, stood at US$309.9 billion in 2025 and is projected to advance at a resilient CAGR of 8.9% from 2025 to 2030, culminating in a forecasted valuation of US$473.8 billion by the end of the period. This growth is driven by the rising elderly population, which is more prone to chronic conditions such as hypertension, diabetes, and cardiovascular diseases, increasing the need for ongoing care at home.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Active Pharmaceutical Ingredients (API) Market by type (Innovative, Generic), Synthesis (synthetic, biotech), Potency (HPAPI), Product (mAbs, hormones), Drug (OTC, Rx), Application (Diabetes, Oncology), Competitive landscape - Global forecast to 2030
The global active pharmaceutical ingredient market, valued at US$136.22 billion in 2024, stood at US$144.20 billion in 2025 and is projected to advance at a resilient CAGR of 6.6% from 2024 to 2030, culminating in a forecasted valuation of US$198.39 billion by the end of the period. The growth of the active pharmaceutical ingredients market is driven by the surge in demand for complex APIs, such as high-potency API, peptides, oligonucleotides, and increasing government incentives and supply chain reshoring.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035
The global biosimilars market, valued at US$32.75 billion in 2024, stood at US$35.04 billion in 2025 and is projected to advance at a resilient CAGR of 7.5% from 2025 to 2035, culminating in a forecasted valuation of US$72.29 billion by the end of the period. This growth is driven by several key factors, including a rising number of regulatory approvals and product launches, the patent expiries of major biologics, and the increasing prevalence of chronic diseases that require effective and affordable treatment options.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
Europe Infusion Pump Market by Product [Accessories (Dedicated, Non-dedicated), Device (Insulin, Syringe, Volumetric, Enteral, PCA Pump)], Application (Chemotherapy, Diabetes, Analgesia), Mode of Administration (Subcutaneous, Epidural) - Forecast to 2031
The Europe infusion pump market, valued at USD 4.78 billion in 2025, stood at USD 5.10 billion in 2026 and is projected to advance at a resilient CAGR of 6.8% from 2026 to 2031, culminating in a forecasted valuation of USD 7.09 billion by the end of the period.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Synthetic Stem Cells Market by Application (Cardiovascular Disease, Neurological Disorders, Other Applications (Cancer, Diabetes, Gastrointestinal, Musculoskeletal Disorders)), Region (North America (US, Canada), Europe, APAC, RoW) - Global Forecast to 2028
The market size for synthetic stem cells is expected to grow from USD 14 million in 2023 to USD 37 million by 2028, at a CAGR of 22.5% during the forecast period. The ethical concerns on the use of embryonic stem cells and the risk of tumor formation and immune response to natural stem cells are the key factors driving the growth of this market. The key developers of synthetic stem cell technology are North Carolina State University (NCSU) (US) and Zhengzhou University (China).
- Published: December 2018
- Price: $ 4950
- TOC Available:
-
Pharmaceutical Drug Delivery Market By Administration Route (Oral, Injectable, Topical, Ocular, Nasal, Transmucosal & Implantable, Pulmonary, Transdermal Patch), Application (Cancer, Diabetes, Cardiovascular), Facility of Use - Global Forecast to 2031
The global pharmaceutical drug delivery market size is expected to reach USD 2,922.82 billion by 2031 from USD 2,152.45 billion in 2026, recording a CAGR of 6.3% during the forecast period. The Key Players Johnson & Johnson Services (US), Pfizer Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lilly and Company (US), Novartis AG (Switzerland), GSK plc (UK), AbbVie Inc. (US), Sanofi (France), Merck & Co., Inc. (US), and Amgen Inc. (US). Some of the prominent players operating in the global pharmaceutical drug delivery devices market include BD (US), Cardinal Health (US), SHL Medical (Switzerland), Gerresheimer AG (Germany), and Stevanato Group (Italy).
- Published: September 2024
- Price: $ 4950
- TOC Available:
-
Telehealth and Telemedicine Market by Function (Teleconsultation, RPM, Diagnostics & Treatment, Analytics, Administrative), Application (TelelCU, Teleradiology, Telecardiology, Diabetes), End User (Hospital, ASC, Payer), & Region - Global Forecast to 2030
The global telehealth and telemedicine market, valued at US$83.62B in 2023, is forecasted to grow at a 11.5% CAGR, reaching US$94.14B by 2024 and US$180.86B by 2030. The telehealth and telemedicine market is experiencing significant growth primarily driven by the growing geriatric and medically underserved (especially rural) populations, the growing prevalence of chronic conditions, the benefits of telehealth & telemedicine given the current shortage of physicians and care personnel, and advancements in telecommunication technologies, and expansion of remote patient monitoring (RPM) systems.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1, GPE, CGRP), Therapeutic Area (Nephrology, Gastroenterology, Genetic, CNS, Obesity, Diabetes), Formulation (Tablet, Capsule) - Global Forecast to 2030
The global oral proteins and peptides market, valued at US$8.07 billion in 2024, stood at US$9.31 billion in 2025 and is projected to advance at a resilient CAGR of 16.4% from 2025 to 2030, culminating in a forecasted valuation of US$19.93 billion by the end of the period. This growth is driven by several factors, including the rising prevalence of chronic diseases such as diabetes, gastrointestinal disorders, and kidney diseases.
- Published: February 2025
- Price: $ 4950
- TOC Available:
-
Asia Pacific Prefilled Syringes Market by Type (Conventional, Safety), Material (Glass Prefilled Syringe, Plastic Syringe), Design (Single-chamber, Dual-chamber), Application (Diabetes, Cancer, Rheumatoid Arthritis, Other), & Country - Forecast to 2030
The Asia Pacific prefilled syringes market, valued at USD 1.56 billion in 2024, stood at USD 1.75 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of USD 3.14 billion by the end of the period.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Electronic Drug Delivery Systems Market by Type (Electronic Wearable Infusion Pump, Autoinjectors, Injection Pens, Electronic Inhalers), Indication (Diabetes, Multiple Sclerosis, Cardiovascular Disease, Asthma & COPD) - Global Forecast to 2024
The electronic drug delivery system market is expected to grow from USD 7.8 billion in 2019 to USD 11.9 billion by 2024, at a compound annual growth rate (CAGR) of 8.7%. during the forecast period.The prominent players in the electronic drug delivery systems market are Insulet Corporation (US), Bayer AG (Germany), Medtronic (Ireland), Novo Nordisk A/S (Denmark), Companion Medical (US), F.Hoffmann-La Roche Ltd (Switzerland), United Therapeutics Corporation (US), AstraZeneca (UK), Tandem Diabetes Care (US), Merck Group (Germany), and Amgen (US).
- Published: October 2019
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
